Pediatric Critical Care Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
CRIPS, Vall d'Hebron Institut of Research (VHIR), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Respir Care. 2021 May;66(5):798-805. doi: 10.4187/respcare.08597. Epub 2021 Mar 9.
The U.S. Centers for Disease Control and Prevention proposed a shift in its surveillance paradigm from ventilator-associated pneumonia to ventilator-associated events (VAE) to broaden the focus of prevention and achieve a greater impact on outcomes. The main objective of the present study was to identify factors associated with pediatric VAEs in children undergoing mechanical ventilation ≥ 48 h.
This was a secondary analysis of a pediatric cohort of a multicenter prospective study. Children who underwent mechanical ventilation ≥ 48 h were included. Exclusion criteria were previous ventilation, extracorporeal life support, and right-to-left shunt or pulmonary hypertension. In the subjects with multiple episodes of mechanical ventilation, only the first episode was considered. Remifentanil and propofol are classified as short-acting sedative and analgesic agents. Pediatric VAE is defined as an "increase in PEEP ≥ 2 cm of HO, an increase in [Formula: see text] of 0.20, or an increase in [Formula: see text] of 0.15 plus an increase in PEEP ≥ 1 cm of HO sustained for ≥1 d. Associations with pediatric VAE were estimated through multivariate Cox proportional hazards analysis. Hazard ratios and 95% CI were computed.
In a cohort of 90 children, 24 pediatric VAEs were documented in 906 ventilator-days. Pediatric VAEs developed after a median of 4.5 (interquartile range, 4-7.25) d. Surgical admissions, spontaneous breathing trials, early mobility, vasopressors, red blood cell units transfusion, type of sedation (continuous vs intermittent), benzodiazepine use for >3 d, and pharmacologic paralysis were not associated with pediatric VAE, whereas the use of continuous short-acting sedative-analgesic agents was identified as a strong protective factor against pediatric VAE (hazard ratio 0.06 [95% CI 0.007-0.5]).
Treatment with short-acting sedative-analgesic agents should be preferred for sedation of mechanically ventilated children in intensive care.
美国疾病控制与预防中心(CDC)提出将其监测模式从呼吸机相关性肺炎(VAP)转变为呼吸机相关性事件(VAE),以扩大预防重点并对结果产生更大影响。本研究的主要目的是确定与机械通气≥48 小时的儿童发生儿科 VAE 相关的因素。
这是一项多中心前瞻性研究的儿科队列的二次分析。纳入机械通气≥48 小时的儿童。排除标准为先前通气、体外生命支持以及右向左分流或肺动脉高压。对于多次机械通气的受试者,仅考虑第一例。瑞芬太尼和丙泊酚被归类为短效镇静和镇痛剂。儿科 VAE 的定义为“PEEP 增加≥2cmH2O,[Formula: see text]增加 0.20,或[Formula: see text]增加 0.15 加上 PEEP 增加≥1cmH2O,持续≥1d”。通过多变量 Cox 比例风险分析估计与儿科 VAE 的关联。计算了危险比和 95%CI。
在 90 名儿童的队列中,在 906 个通气日中记录了 24 例儿科 VAE。儿科 VAE 在中位数为 4.5(四分位距,4-7.25)天后发生。手术入院、自主呼吸试验、早期活动、血管加压素、红细胞单位输血、镇静类型(连续 vs 间歇)、苯二氮䓬类药物使用超过 3d、以及药物性瘫痪与儿科 VAE 无关,而连续使用短效镇静镇痛剂被确定为儿科 VAE 的强有力保护因素(危险比 0.06[95%CI 0.007-0.5])。
对于重症监护病房机械通气的儿童,应首选使用短效镇静镇痛剂进行镇静。